We caught up with Laura Coates (University of Oxford, Oxford, UK) to discuss the results from FUTURE 5, the phase 3 study of secukinumab in patients with psoriatic arthritis (Clinical Trial Identifier: NCT02404350). The abstract ‘Achievement of Sustained Remission and Low Disease Activity with Secukinumab Improves Quality of Life and Physical Function in Patients with Psoriatic Arthritis: Results from a Randomized Phase 3 Study’ (ABSTRACT NUMBER: 0353) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
Questions
- What is the rationale for the treat to target approach in psoriatic arthritis? (0:12)
- What are the advantages and limitations of remission and low disease activity as clinical endpoints? (0:49)
- Could you tell us a little about the aims and design of the FUTURE 5 study? (2:41)
- What were the major findings of this study in terms of remission and low disease activity, and how did these correlate to quality of life and physical function? (3:06)
- What are the implications of these findings, both for clinical practice and future clinical trial design? (4:39)
Disclosures: Laura Coates reports receiving: Honoraria, grant/research support or consulting fees from AbbVie, Amgen, Boehringer-Ingelheim, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Sun Pharma, and UCB; and is a member of a speakers’ bureau for AbbVie, Amgen, Biogen, BMS, Celgene, Eli Lilly, Janssen, Medac, Novartis, Pfizer, Sun Pharma, and UCB.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR Convergence 2020 (Virtual).
